| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
The primary targets of (E)-3,4-Dimethoxycinnamic acid include oxidative stress pathways, inflammatory mediators, and microbial pathogens. It exhibits antioxidant activity by scavenging free radicals and inhibiting lipid peroxidation. The compound also shows anti-inflammatory effects by reducing the production of pro-inflammatory cytokines and inhibiting COX-2 activity. It has antimicrobial activity against various bacterial and fungal strains.
|
|---|---|
| ln Vitro |
In L-02 cells exposed to ethanol, 3,4-Dimethoxycinnamic acid (Methyl ferulic acid; 25, 50, and 100 µM) reduces the apoptosis caused by ethanol[1]. At 25, 50, and 100 µM, 3,4-dimethoxycinnamic acid inhibits the expression levels of p22phox and Nox4 in L-02 cells[1]. In L-02 cells, treatment with 3,4-dimethoxycinnamic acid at 25, 50, and 100 µM reduces the activation of MAPK caused by ethanol[1].
In vitro, (E)-3,4-Dimethoxycinnamic acid demonstrates antioxidant activity in DPPH and ABTS assays. It shows anti-inflammatory effects by reducing NO production and IL-6 secretion in LPS-stimulated macrophages. The compound also inhibits the growth of Gram-positive and Gram-negative bacteria, with MIC values typically in the range of 50-200 µg/mL. It has been studied in various cell models, including RAW 264.7 macrophages and cancer cell lines. |
| ln Vivo |
In vivo activity of (E)-3,4-Dimethoxycinnamic acid has been reported in some animal models of inflammation, showing reduction of edema and inflammatory markers. However, comprehensive pharmacokinetic and pharmacodynamic data are limited. The compound is primarily studied in vitro, and further in vivo studies are needed to confirm its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for (E)-3,4-Dimethoxycinnamic acid typically involve antioxidant assays (DPPH, ABTS, FRAP), anti-inflammatory assays (measuring NO, PGE2, and cytokines in macrophages), and antimicrobial susceptibility testing. The compound is tested at concentrations ranging from 1 to 1000 µM.
|
| Cell Assay |
In vitro cellular assays for (E)-3,4-Dimethoxycinnamic acid involve testing its effects on cell viability, inflammatory markers, and microbial growth. Macrophages are stimulated with LPS and treated with the compound; cytokine levels are measured by ELISA. Bacterial and fungal cultures are treated with serial dilutions, and MIC values are determined. The compound shows concentration-dependent activities.
|
| Animal Protocol |
In vivo animal studies for (E)-3,4-Dimethoxycinnamic acid are limited. For anti-inflammatory testing, carrageenan-induced paw edema in rats is a common model, with oral or intraperitoneal administration of the compound at doses of 10-50 mg/kg. For antimicrobial testing, infection models could be used, but detailed protocols are not well reported.
|
| ADME/Pharmacokinetics |
(E)-3,4-Dimethoxycinnamic acid has a molecular formula of C11H12O4 and a molecular weight of 208.21. It appears as a solid powder with a purity of ≥98%. It is soluble in DMSO and ethanol, but poorly soluble in water. The compound should be stored at -20°C, protected from light, and is stable for up to 2 years under dry conditions. It is intended for research use only and is not for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (E)-3,4-Dimethoxycinnamic acid has not been extensively characterized. As a natural compound, it is generally considered to have low toxicity. Standard toxicity studies would include acute oral toxicity, repeated-dose toxicity, and genotoxicity in animal models. The compound is intended for research use only and is not approved for clinical use.
|
| References | |
| Additional Infomation |
3,4-Dimethoxycinnamic acid is a methoxycinnamic acid, a product of trans-cinnamic acid with methoxy groups substituted at the 3' and 4' positions. Functionally, it is related to trans-cinnamic acid. It is the conjugate acid of 3,4-dimethoxy-(E)-cinnamic ester. 3,4-Dimethoxycinnamic acid has been reported to exist in Bacopa monnieri, Populus nigra, and several other organisms with relevant data.
(E)-3,4-Dimethoxycinnamic acid (CAS 14737-89-4) is a naturally occurring cinnamic acid derivative found in various plants. It has a molecular formula of C11H12O4 and a molecular weight of 208.21. The compound exhibits antioxidant, anti-inflammatory, and antimicrobial activities. It scavenges free radicals, inhibits pro-inflammatory mediators, and shows antimicrobial effects. It is intended for research use only and is not approved for clinical use. |
| Molecular Formula |
C11H12O4
|
|---|---|
| Molecular Weight |
208.21
|
| Exact Mass |
208.073
|
| CAS # |
14737-89-4
|
| PubChem CID |
717531
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
367.4±27.0 °C at 760 mmHg
|
| Melting Point |
181-183ºC(lit.)
|
| Flash Point |
144.0±17.2 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.574
|
| LogP |
2.24
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
15
|
| Complexity |
237
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=C(C=C1)/C=C/C(=O)O)OC
|
| InChi Key |
HJBWJAPEBGSQPR-GQCTYLIASA-N
|
| InChi Code |
InChI=1S/C11H12O4/c1-14-9-5-3-8(4-6-11(12)13)7-10(9)15-2/h3-7H,1-2H3,(H,12,13)/b6-4+
|
| Chemical Name |
(E)-3-(3,4-dimethoxyphenyl)prop-2-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (240.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.01 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.01 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.01 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8028 mL | 24.0142 mL | 48.0284 mL | |
| 5 mM | 0.9606 mL | 4.8028 mL | 9.6057 mL | |
| 10 mM | 0.4803 mL | 2.4014 mL | 4.8028 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
